💼 Business 2d ago · Ekta Bagri

BDTX: What Silevertinib Data Say About EGFR NSCLC Upside

Quartz (QZ)

Global business news for the new economy

Source ↗ 👁 1 💬 0

BDTX bets on silevertinib's broad EGFR mutation reach and CNS activity, but with no approved products, upcoming 2026 data and partnerships are pivotal.

Comments (0)

More Like This

📰

Why is quantum computing seen as a challenge to Bitcoin?

All News · 2h ago

BitMEX Report Finds 500%+ Increase in Tokenised Commodities and Equity Perpetuals

All News · 3h ago

Japan targets Asian oil alliance as supply bottlenecks persist

All News · 3h ago

Money to burn? The humble matchbox gets a £235 makeover

Business | The Guardian · 3h ago

Low-tax Texas opens London office to lure jobs and investment

Business | The Guardian · 3h ago

Taemin Dazzles At Coachella Debut, Premieres 6 New Songs: Full Setlist

Forbes - Business · 3h ago